Evidence map›Paper›PMID 41407463›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[The clinical study of azacitidine and lenalidomide combination in myelodysplastic neoplasm patients with TP53 mutations].

X Yan, C H Guo, C Yang, C Q Lin, D D Song, Z M Cai, Y Wang, L Wang, Z Ge

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

X YanDepartment of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
C H GuoDepartment of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
C YangDepartment of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
C Q LinDepartment of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
D D SongDepartment of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
Z M CaiThe Affiliated Lianyungang Hospital of Xuzhou Medical University / The First People's Hospital of Lianyungang, Lianyungang 222000, China.
Y WangThe Affiliated Lianyungang Hospital of Xuzhou Medical University / The First People's Hospital of Lianyungang, Lianyungang 222000, China.
L WangXuyi People's Hospital, Xuyi 211700, China.
Z GeDepartment of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.

Funding

Jiangsu Provincial Medical Key Discipline (Laboratory) Cultivation Unit JSDW202212Medical research key projects-Jiangsu Commission of Health ZD2021003Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Pairing Assistance Construction Funds zdlyg03,zdyyxy15
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AzacitidineLenalidomideMyelodysplastic SyndromesTumor Suppressor Protein p53AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedMutationTreatment OutcomeAzacitidineLenalidomideTP53 protein, humanTumor Suppressor Protein p53AzacitidineLenalidomideMyelodysplastic neoplasmTP53 mutationTreatment outcome

Identifiers

PMID41407463
PMCPMC12708943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.